| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatectomy | 80 | 2024 | 1012 | 8.660 |
Why?
|
| Pancreatectomy | 40 | 2024 | 696 | 8.420 |
Why?
|
| Pancreatic Neoplasms | 88 | 2024 | 5233 | 8.130 |
Why?
|
| Pancreaticoduodenectomy | 36 | 2024 | 705 | 6.940 |
Why?
|
| Carcinoma, Pancreatic Ductal | 43 | 2024 | 1817 | 6.600 |
Why?
|
| Analgesics, Opioid | 21 | 2024 | 1457 | 4.790 |
Why?
|
| Liver Neoplasms | 81 | 2024 | 4787 | 4.780 |
Why?
|
| Adenocarcinoma | 48 | 2024 | 7938 | 4.750 |
Why?
|
| Pain, Postoperative | 17 | 2024 | 654 | 4.520 |
Why?
|
| Colorectal Neoplasms | 52 | 2024 | 3657 | 3.690 |
Why?
|
| Practice Patterns, Physicians' | 14 | 2022 | 1318 | 3.330 |
Why?
|
| Drug Prescriptions | 8 | 2022 | 323 | 2.900 |
Why?
|
| Postoperative Complications | 39 | 2024 | 5690 | 2.860 |
Why?
|
| Surgical Oncology | 7 | 2020 | 208 | 2.800 |
Why?
|
| Portal Vein | 15 | 2024 | 364 | 2.710 |
Why?
|
| Neoadjuvant Therapy | 49 | 2024 | 5188 | 2.430 |
Why?
|
| Pancreatic Fistula | 11 | 2023 | 103 | 2.290 |
Why?
|
| Patient Discharge | 9 | 2023 | 707 | 2.270 |
Why?
|
| Venous Thromboembolism | 8 | 2022 | 366 | 1.980 |
Why?
|
| Robotic Surgical Procedures | 15 | 2024 | 528 | 1.930 |
Why?
|
| Retrospective Studies | 124 | 2024 | 39710 | 1.910 |
Why?
|
| Propensity Score | 11 | 2024 | 774 | 1.810 |
Why?
|
| Gallbladder Neoplasms | 10 | 2023 | 245 | 1.780 |
Why?
|
| Critical Pathways | 8 | 2024 | 159 | 1.750 |
Why?
|
| Cholangiocarcinoma | 13 | 2024 | 497 | 1.670 |
Why?
|
| Bile Duct Neoplasms | 13 | 2024 | 494 | 1.670 |
Why?
|
| Amylases | 2 | 2023 | 67 | 1.590 |
Why?
|
| Blood Transfusion | 8 | 2021 | 580 | 1.590 |
Why?
|
| Humans | 264 | 2024 | 271076 | 1.580 |
Why?
|
| Aged | 125 | 2024 | 73177 | 1.470 |
Why?
|
| Gastric Bypass | 2 | 2022 | 92 | 1.410 |
Why?
|
| Perioperative Care | 6 | 2022 | 445 | 1.370 |
Why?
|
| Mesenteric Veins | 6 | 2024 | 83 | 1.360 |
Why?
|
| Prognosis | 74 | 2024 | 22463 | 1.360 |
Why?
|
| Middle Aged | 127 | 2024 | 90070 | 1.350 |
Why?
|
| CA-19-9 Antigen | 8 | 2024 | 155 | 1.240 |
Why?
|
| Aged, 80 and over | 64 | 2024 | 30937 | 1.180 |
Why?
|
| Survival Rate | 57 | 2024 | 12519 | 1.180 |
Why?
|
| Gastrectomy | 8 | 2024 | 476 | 1.170 |
Why?
|
| Male | 135 | 2024 | 128555 | 1.170 |
Why?
|
| Liver | 11 | 2024 | 3127 | 1.160 |
Why?
|
| Laparoscopy | 13 | 2023 | 1292 | 1.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 30 | 2024 | 16592 | 1.130 |
Why?
|
| Neoplasm Recurrence, Local | 29 | 2023 | 10349 | 1.120 |
Why?
|
| Female | 139 | 2024 | 148608 | 1.100 |
Why?
|
| Retroperitoneal Neoplasms | 4 | 2019 | 299 | 1.080 |
Why?
|
| Quality Improvement | 4 | 2020 | 917 | 1.070 |
Why?
|
| Embolization, Therapeutic | 8 | 2021 | 605 | 1.010 |
Why?
|
| Inpatients | 5 | 2022 | 691 | 1.000 |
Why?
|
| Surgeons | 3 | 2021 | 484 | 0.990 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2021 | 640 | 0.990 |
Why?
|
| Patient Readmission | 6 | 2023 | 591 | 0.990 |
Why?
|
| Cholecystectomy | 5 | 2021 | 118 | 0.980 |
Why?
|
| Venous Thrombosis | 2 | 2019 | 378 | 0.980 |
Why?
|
| Neoplasm Staging | 34 | 2024 | 13975 | 0.970 |
Why?
|
| Postoperative Hemorrhage | 4 | 2018 | 137 | 0.950 |
Why?
|
| Esophagectomy | 4 | 2024 | 946 | 0.950 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 631 | 0.930 |
Why?
|
| Fibrinolytic Agents | 3 | 2016 | 302 | 0.930 |
Why?
|
| Methocarbamol | 1 | 2023 | 2 | 0.930 |
Why?
|
| Chemotherapy, Adjuvant | 21 | 2024 | 3972 | 0.910 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 707 | 0.910 |
Why?
|
| Adult | 85 | 2024 | 81614 | 0.900 |
Why?
|
| Bupivacaine | 1 | 2024 | 74 | 0.900 |
Why?
|
| Preoperative Care | 11 | 2021 | 1548 | 0.900 |
Why?
|
| Follow-Up Studies | 33 | 2021 | 15256 | 0.880 |
Why?
|
| Habits | 2 | 2020 | 37 | 0.880 |
Why?
|
| Opioid-Related Disorders | 3 | 2022 | 417 | 0.850 |
Why?
|
| Colectomy | 3 | 2017 | 291 | 0.840 |
Why?
|
| Anesthetics, Local | 1 | 2024 | 176 | 0.840 |
Why?
|
| Blood Loss, Surgical | 5 | 2024 | 294 | 0.830 |
Why?
|
| Lymph Node Excision | 8 | 2022 | 2044 | 0.820 |
Why?
|
| Nerve Block | 1 | 2024 | 185 | 0.800 |
Why?
|
| Gastric Outlet Obstruction | 1 | 2022 | 30 | 0.800 |
Why?
|
| Liposomes | 1 | 2024 | 713 | 0.790 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 2022 | 63 | 0.790 |
Why?
|
| Risk Assessment | 16 | 2023 | 6837 | 0.790 |
Why?
|
| Treatment Outcome | 53 | 2024 | 33833 | 0.770 |
Why?
|
| Carcinoma, Hepatocellular | 11 | 2024 | 2159 | 0.760 |
Why?
|
| Risk Factors | 29 | 2023 | 17835 | 0.740 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 2426 | 0.740 |
Why?
|
| Surgical Procedures, Operative | 2 | 2021 | 355 | 0.730 |
Why?
|
| Bile Ducts | 2 | 2018 | 115 | 0.730 |
Why?
|
| Time Factors | 24 | 2024 | 13130 | 0.710 |
Why?
|
| Appointments and Schedules | 1 | 2020 | 98 | 0.690 |
Why?
|
| Digestive System Neoplasms | 2 | 2020 | 77 | 0.690 |
Why?
|
| Digestive System Surgical Procedures | 3 | 2023 | 278 | 0.690 |
Why?
|
| Neoplasms | 9 | 2024 | 15838 | 0.690 |
Why?
|
| Patient Selection | 6 | 2020 | 2043 | 0.690 |
Why?
|
| Pain Measurement | 1 | 2024 | 1011 | 0.690 |
Why?
|
| Hepatic Insufficiency | 2 | 2017 | 31 | 0.690 |
Why?
|
| Prospective Studies | 21 | 2024 | 13353 | 0.690 |
Why?
|
| Morbidity | 6 | 2019 | 403 | 0.690 |
Why?
|
| Gastroparesis | 1 | 2020 | 81 | 0.680 |
Why?
|
| Common Bile Duct | 1 | 2019 | 28 | 0.670 |
Why?
|
| Intraoperative Complications | 2 | 2019 | 288 | 0.660 |
Why?
|
| Blood Coagulation | 2 | 2017 | 169 | 0.660 |
Why?
|
| Deoxycytidine | 10 | 2022 | 1377 | 0.630 |
Why?
|
| Anastomotic Leak | 1 | 2019 | 83 | 0.630 |
Why?
|
| Fluorouracil | 13 | 2024 | 1984 | 0.630 |
Why?
|
| Leucovorin | 10 | 2024 | 343 | 0.620 |
Why?
|
| Stomach Neoplasms | 5 | 2024 | 2317 | 0.620 |
Why?
|
| Duodenal Neoplasms | 2 | 2017 | 139 | 0.610 |
Why?
|
| Vascular Patency | 1 | 2018 | 191 | 0.590 |
Why?
|
| Texas | 12 | 2021 | 6417 | 0.580 |
Why?
|
| Clinical Decision-Making | 2 | 2020 | 535 | 0.580 |
Why?
|
| Education, Medical, Graduate | 2 | 2020 | 698 | 0.570 |
Why?
|
| ErbB Receptors | 5 | 2011 | 2379 | 0.570 |
Why?
|
| Teratoma | 1 | 2019 | 255 | 0.560 |
Why?
|
| Lymphatic Metastasis | 11 | 2021 | 4968 | 0.550 |
Why?
|
| Length of Stay | 8 | 2024 | 2013 | 0.550 |
Why?
|
| Sarcoma | 6 | 2020 | 1840 | 0.550 |
Why?
|
| Thrombophilia | 1 | 2016 | 56 | 0.540 |
Why?
|
| Vascular Surgical Procedures | 2 | 2018 | 615 | 0.540 |
Why?
|
| Thrombelastography | 1 | 2016 | 65 | 0.530 |
Why?
|
| Prosthesis-Related Infections | 1 | 2018 | 228 | 0.530 |
Why?
|
| Albumins | 5 | 2022 | 267 | 0.530 |
Why?
|
| Young Adult | 26 | 2020 | 22062 | 0.510 |
Why?
|
| United States | 22 | 2024 | 15989 | 0.510 |
Why?
|
| Cardia | 1 | 2014 | 45 | 0.490 |
Why?
|
| Hepatic Veins | 3 | 2020 | 59 | 0.490 |
Why?
|
| Healthcare Disparities | 3 | 2023 | 647 | 0.480 |
Why?
|
| Multivariate Analysis | 11 | 2021 | 4332 | 0.470 |
Why?
|
| Rectal Neoplasms | 4 | 2023 | 1237 | 0.470 |
Why?
|
| Robotics | 3 | 2023 | 365 | 0.460 |
Why?
|
| Proportional Hazards Models | 13 | 2024 | 5087 | 0.460 |
Why?
|
| Curriculum | 1 | 2020 | 915 | 0.460 |
Why?
|
| Transforming Growth Factor beta | 1 | 2019 | 1133 | 0.450 |
Why?
|
| Mutation | 24 | 2024 | 15855 | 0.450 |
Why?
|
| Stents | 2 | 2023 | 1006 | 0.450 |
Why?
|
| Biomarkers, Tumor | 14 | 2024 | 10698 | 0.450 |
Why?
|
| Incidence | 10 | 2023 | 5845 | 0.430 |
Why?
|
| Predictive Value of Tests | 9 | 2024 | 4984 | 0.420 |
Why?
|
| Research Design | 1 | 2020 | 1568 | 0.410 |
Why?
|
| Postoperative Care | 4 | 2021 | 729 | 0.410 |
Why?
|
| Margins of Excision | 8 | 2022 | 314 | 0.410 |
Why?
|
| Operative Time | 5 | 2023 | 244 | 0.410 |
Why?
|
| Multidetector Computed Tomography | 2 | 2020 | 148 | 0.400 |
Why?
|
| Klatskin Tumor | 2 | 2022 | 30 | 0.400 |
Why?
|
| Combined Modality Therapy | 15 | 2024 | 9042 | 0.400 |
Why?
|
| Decision Making | 2 | 2020 | 1244 | 0.400 |
Why?
|
| Cohort Studies | 11 | 2023 | 9434 | 0.380 |
Why?
|
| Cost-Benefit Analysis | 4 | 2024 | 965 | 0.380 |
Why?
|
| Genes, erbB-1 | 2 | 2010 | 103 | 0.370 |
Why?
|
| Clinical Trials as Topic | 2 | 2020 | 3866 | 0.370 |
Why?
|
| Bile Ducts, Intrahepatic | 5 | 2023 | 331 | 0.370 |
Why?
|
| Lymph Nodes | 6 | 2023 | 3067 | 0.370 |
Why?
|
| SEER Program | 1 | 2014 | 1044 | 0.360 |
Why?
|
| Biliary Tract Neoplasms | 2 | 2023 | 179 | 0.360 |
Why?
|
| Drainage | 2 | 2023 | 449 | 0.350 |
Why?
|
| Paclitaxel | 5 | 2022 | 2099 | 0.350 |
Why?
|
| Health Status | 1 | 2013 | 626 | 0.350 |
Why?
|
| Kaplan-Meier Estimate | 10 | 2020 | 6249 | 0.350 |
Why?
|
| Cholecystectomy, Laparoscopic | 2 | 2021 | 75 | 0.350 |
Why?
|
| Catheter Ablation | 2 | 2012 | 575 | 0.350 |
Why?
|
| Common Bile Duct Neoplasms | 2 | 2023 | 150 | 0.340 |
Why?
|
| Ampulla of Vater | 2 | 2023 | 158 | 0.340 |
Why?
|
| Bilirubin | 3 | 2024 | 225 | 0.340 |
Why?
|
| Abdominal Neoplasms | 2 | 2024 | 248 | 0.340 |
Why?
|
| Neuroendocrine Tumors | 3 | 2021 | 651 | 0.330 |
Why?
|
| Reoperation | 4 | 2019 | 1390 | 0.330 |
Why?
|
| Population Surveillance | 1 | 2013 | 649 | 0.330 |
Why?
|
| Databases, Factual | 8 | 2024 | 2288 | 0.330 |
Why?
|
| Circulating Tumor DNA | 2 | 2022 | 271 | 0.320 |
Why?
|
| Chemoradiotherapy, Adjuvant | 3 | 2018 | 562 | 0.310 |
Why?
|
| Early Detection of Cancer | 1 | 2016 | 1325 | 0.300 |
Why?
|
| Tomography, X-Ray Computed | 16 | 2024 | 7784 | 0.300 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2019 | 1409 | 0.300 |
Why?
|
| Perception | 2 | 2020 | 351 | 0.290 |
Why?
|
| Smad4 Protein | 2 | 2019 | 200 | 0.290 |
Why?
|
| Disease-Free Survival | 14 | 2021 | 10250 | 0.290 |
Why?
|
| Antineoplastic Agents | 10 | 2021 | 14678 | 0.280 |
Why?
|
| Mesenteric Artery, Superior | 2 | 2024 | 77 | 0.280 |
Why?
|
| Tumor Suppressor Protein p53 | 6 | 2022 | 3657 | 0.280 |
Why?
|
| Metastasectomy | 2 | 2020 | 209 | 0.280 |
Why?
|
| Betacoronavirus | 3 | 2020 | 520 | 0.280 |
Why?
|
| Kentucky | 2 | 2016 | 28 | 0.270 |
Why?
|
| Radiotherapy, Adjuvant | 6 | 2017 | 2266 | 0.260 |
Why?
|
| Chi-Square Distribution | 3 | 2013 | 1326 | 0.260 |
Why?
|
| ras Proteins | 2 | 2020 | 803 | 0.260 |
Why?
|
| Gene Dosage | 2 | 2009 | 827 | 0.260 |
Why?
|
| Pancreas | 4 | 2023 | 744 | 0.250 |
Why?
|
| Pilot Projects | 3 | 2021 | 2851 | 0.250 |
Why?
|
| Incidental Findings | 4 | 2019 | 280 | 0.250 |
Why?
|
| Odds Ratio | 4 | 2013 | 2288 | 0.240 |
Why?
|
| Radiotherapy Dosage | 4 | 2024 | 4001 | 0.240 |
Why?
|
| Heparin | 2 | 2017 | 346 | 0.240 |
Why?
|
| Age Factors | 5 | 2018 | 5497 | 0.230 |
Why?
|
| Adolescent | 13 | 2019 | 32595 | 0.230 |
Why?
|
| Laparotomy | 3 | 2024 | 228 | 0.230 |
Why?
|
| Cholangitis | 1 | 2024 | 51 | 0.230 |
Why?
|
| Colonic Neoplasms | 2 | 2022 | 1437 | 0.230 |
Why?
|
| Hospital Costs | 3 | 2024 | 252 | 0.230 |
Why?
|
| Pain Management | 2 | 2020 | 716 | 0.230 |
Why?
|
| Incisional Hernia | 1 | 2023 | 14 | 0.220 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2009 | 920 | 0.220 |
Why?
|
| Postoperative Period | 2 | 2020 | 671 | 0.220 |
Why?
|
| Biliary Tract | 1 | 2023 | 36 | 0.220 |
Why?
|
| Celecoxib | 1 | 2023 | 203 | 0.220 |
Why?
|
| Morphine | 2 | 2022 | 332 | 0.220 |
Why?
|
| Survival Analysis | 9 | 2021 | 9309 | 0.220 |
Why?
|
| Breast Neoplasms | 4 | 2020 | 16184 | 0.220 |
Why?
|
| Genes, ras | 4 | 2021 | 680 | 0.220 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 2023 | 44 | 0.210 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2023 | 508 | 0.210 |
Why?
|
| Chromosome Aberrations | 1 | 2010 | 2022 | 0.210 |
Why?
|
| Hypertension, Portal | 1 | 2024 | 129 | 0.210 |
Why?
|
| Interviews as Topic | 2 | 2024 | 516 | 0.210 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2024 | 340 | 0.210 |
Why?
|
| Pandemics | 3 | 2020 | 1596 | 0.210 |
Why?
|
| Acetaminophen | 1 | 2023 | 126 | 0.210 |
Why?
|
| Carbohydrates | 1 | 2022 | 64 | 0.210 |
Why?
|
| Cystic Duct | 2 | 2019 | 10 | 0.200 |
Why?
|
| Aftercare | 1 | 2023 | 254 | 0.200 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2024 | 916 | 0.200 |
Why?
|
| Peritoneal Neoplasms | 2 | 2020 | 851 | 0.200 |
Why?
|
| Chemoradiotherapy | 5 | 2019 | 2029 | 0.200 |
Why?
|
| Elective Surgical Procedures | 2 | 2013 | 247 | 0.200 |
Why?
|
| Pancreatitis, Chronic | 1 | 2022 | 127 | 0.200 |
Why?
|
| Pancreatic Cyst | 1 | 2022 | 115 | 0.200 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2021 | 963 | 0.190 |
Why?
|
| Device Removal | 1 | 2023 | 337 | 0.190 |
Why?
|
| Sarcopenia | 2 | 2020 | 113 | 0.190 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2024 | 338 | 0.190 |
Why?
|
| Qualitative Research | 1 | 2024 | 623 | 0.190 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2024 | 379 | 0.190 |
Why?
|
| Anticoagulants | 2 | 2017 | 784 | 0.180 |
Why?
|
| Harm Reduction | 1 | 2020 | 16 | 0.180 |
Why?
|
| Exercise Therapy | 2 | 2023 | 290 | 0.180 |
Why?
|
| Gastric Emptying | 1 | 2020 | 100 | 0.180 |
Why?
|
| Liquid Biopsy | 1 | 2021 | 162 | 0.180 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2021 | 132 | 0.180 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 2020 | 43 | 0.180 |
Why?
|
| Organ Size | 5 | 2024 | 725 | 0.180 |
Why?
|
| GTP Phosphohydrolases | 2 | 2019 | 341 | 0.180 |
Why?
|
| Diagnostic Imaging | 2 | 2009 | 1178 | 0.180 |
Why?
|
| Biology | 1 | 2020 | 76 | 0.180 |
Why?
|
| Surveys and Questionnaires | 4 | 2020 | 5898 | 0.170 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2024 | 508 | 0.170 |
Why?
|
| Inappropriate Prescribing | 1 | 2020 | 52 | 0.170 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2024 | 5516 | 0.170 |
Why?
|
| Personnel Selection | 1 | 2020 | 85 | 0.170 |
Why?
|
| Feasibility Studies | 3 | 2021 | 2346 | 0.170 |
Why?
|
| Internship and Residency | 2 | 2020 | 1433 | 0.160 |
Why?
|
| Patient-Specific Modeling | 1 | 2018 | 28 | 0.160 |
Why?
|
| Intestinal Neoplasms | 1 | 2020 | 201 | 0.160 |
Why?
|
| Phlebography | 1 | 2018 | 67 | 0.160 |
Why?
|
| Cisplatin | 3 | 2023 | 2493 | 0.160 |
Why?
|
| Signal Transduction | 5 | 2021 | 12207 | 0.160 |
Why?
|
| Triage | 1 | 2020 | 257 | 0.160 |
Why?
|
| Disease Progression | 4 | 2019 | 6896 | 0.160 |
Why?
|
| Neoplasm Metastasis | 3 | 2021 | 5324 | 0.160 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2024 | 851 | 0.150 |
Why?
|
| Interprofessional Relations | 1 | 2020 | 211 | 0.150 |
Why?
|
| Body Composition | 2 | 2020 | 609 | 0.150 |
Why?
|
| Cooperative Behavior | 1 | 2020 | 306 | 0.150 |
Why?
|
| Neoplasm, Residual | 3 | 2019 | 1740 | 0.150 |
Why?
|
| Lung Neoplasms | 3 | 2024 | 11758 | 0.150 |
Why?
|
| Erlotinib Hydrochloride | 3 | 2010 | 397 | 0.150 |
Why?
|
| Logistic Models | 3 | 2013 | 3437 | 0.150 |
Why?
|
| Splenic Vein | 1 | 2017 | 16 | 0.150 |
Why?
|
| Efficiency | 1 | 2018 | 93 | 0.150 |
Why?
|
| Intraoperative Care | 1 | 2019 | 274 | 0.150 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2018 | 172 | 0.150 |
Why?
|
| Quality of Life | 2 | 2023 | 4725 | 0.150 |
Why?
|
| Vena Cava, Inferior | 1 | 2018 | 196 | 0.150 |
Why?
|
| Models, Cardiovascular | 1 | 2018 | 189 | 0.150 |
Why?
|
| Muscular Atrophy | 1 | 2018 | 107 | 0.150 |
Why?
|
| Bacterial Infections | 1 | 2021 | 507 | 0.150 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2020 | 649 | 0.150 |
Why?
|
| Splenic Artery | 1 | 2017 | 53 | 0.140 |
Why?
|
| Liver Failure | 1 | 2018 | 142 | 0.140 |
Why?
|
| Carcinoma in Situ | 1 | 2021 | 495 | 0.140 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 319 | 0.140 |
Why?
|
| Hospital Mortality | 4 | 2021 | 1315 | 0.140 |
Why?
|
| General Surgery | 1 | 2020 | 328 | 0.140 |
Why?
|
| Career Mobility | 1 | 2018 | 89 | 0.140 |
Why?
|
| Enoxaparin | 1 | 2017 | 57 | 0.140 |
Why?
|
| Pancreatic Ducts | 1 | 2018 | 128 | 0.140 |
Why?
|
| Walking | 1 | 2019 | 273 | 0.140 |
Why?
|
| Preoperative Period | 4 | 2020 | 349 | 0.140 |
Why?
|
| Ipilimumab | 1 | 2022 | 758 | 0.140 |
Why?
|
| Liver Transplantation | 2 | 2016 | 1185 | 0.140 |
Why?
|
| Software | 1 | 2024 | 1361 | 0.140 |
Why?
|
| Palliative Care | 2 | 2022 | 2152 | 0.140 |
Why?
|
| Atrophy | 1 | 2017 | 280 | 0.140 |
Why?
|
| Computed Tomography Angiography | 1 | 2018 | 247 | 0.140 |
Why?
|
| Liver Regeneration | 1 | 2017 | 134 | 0.140 |
Why?
|
| Social Support | 1 | 2019 | 585 | 0.140 |
Why?
|
| Serum Albumin | 2 | 2014 | 249 | 0.140 |
Why?
|
| Gastrointestinal Stromal Tumors | 2 | 2009 | 319 | 0.140 |
Why?
|
| Fluid Therapy | 1 | 2017 | 189 | 0.140 |
Why?
|
| Diaphragm | 1 | 2017 | 187 | 0.130 |
Why?
|
| Thyroidectomy | 1 | 2019 | 495 | 0.130 |
Why?
|
| Carcinoma, Lobular | 1 | 2020 | 617 | 0.130 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 408 | 0.130 |
Why?
|
| Treatment Failure | 1 | 2019 | 1433 | 0.130 |
Why?
|
| Leiomyosarcoma | 1 | 2017 | 255 | 0.130 |
Why?
|
| Case-Control Studies | 4 | 2023 | 6027 | 0.130 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 2016 | 43 | 0.130 |
Why?
|
| Cystadenoma, Mucinous | 1 | 2015 | 35 | 0.130 |
Why?
|
| Chile | 3 | 2019 | 68 | 0.130 |
Why?
|
| Dexamethasone | 1 | 2020 | 1505 | 0.130 |
Why?
|
| Liposarcoma | 1 | 2017 | 247 | 0.130 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2018 | 441 | 0.120 |
Why?
|
| Neoplasm Invasiveness | 6 | 2019 | 4067 | 0.120 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2017 | 339 | 0.120 |
Why?
|
| Microvessels | 1 | 2016 | 139 | 0.120 |
Why?
|
| Biomarkers | 3 | 2022 | 5107 | 0.120 |
Why?
|
| Faculty, Medical | 1 | 2018 | 308 | 0.120 |
Why?
|
| Cholestasis, Intrahepatic | 1 | 2015 | 71 | 0.120 |
Why?
|
| Health Expenditures | 1 | 2016 | 201 | 0.120 |
Why?
|
| Analgesia, Epidural | 1 | 2015 | 101 | 0.120 |
Why?
|
| Patient Care Team | 1 | 2020 | 826 | 0.120 |
Why?
|
| Quinazolines | 3 | 2010 | 953 | 0.120 |
Why?
|
| Health Policy | 1 | 2017 | 282 | 0.120 |
Why?
|
| Radiosurgery | 1 | 2023 | 1370 | 0.120 |
Why?
|
| Drug Administration Schedule | 2 | 2017 | 3543 | 0.120 |
Why?
|
| Hypertrophy | 3 | 2020 | 159 | 0.110 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 869 | 0.110 |
Why?
|
| Melanoma | 2 | 2021 | 5524 | 0.110 |
Why?
|
| Bile Duct Diseases | 1 | 2013 | 46 | 0.110 |
Why?
|
| Carcinoembryonic Antigen | 2 | 2024 | 237 | 0.110 |
Why?
|
| Hospitalization | 2 | 2024 | 2201 | 0.110 |
Why?
|
| Camptothecin | 2 | 2013 | 538 | 0.110 |
Why?
|
| Quality of Health Care | 1 | 2018 | 626 | 0.110 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2020 | 1233 | 0.110 |
Why?
|
| Transfusion Reaction | 1 | 2013 | 101 | 0.110 |
Why?
|
| Emergency Treatment | 1 | 2014 | 105 | 0.110 |
Why?
|
| Health Care Costs | 1 | 2018 | 700 | 0.110 |
Why?
|
| Pain | 2 | 2023 | 1692 | 0.100 |
Why?
|
| Office Visits | 1 | 2013 | 95 | 0.100 |
Why?
|
| Markov Chains | 1 | 2013 | 180 | 0.100 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2022 | 1335 | 0.100 |
Why?
|
| Cell Line, Tumor | 6 | 2019 | 14864 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 2 | 2023 | 3176 | 0.100 |
Why?
|
| Cancer Survivors | 1 | 2019 | 740 | 0.100 |
Why?
|
| Tumor Burden | 4 | 2021 | 2034 | 0.100 |
Why?
|
| Lung Diseases | 1 | 2017 | 751 | 0.100 |
Why?
|
| Asymptomatic Diseases | 1 | 2012 | 104 | 0.100 |
Why?
|
| Membrane Proteins | 2 | 2019 | 2953 | 0.100 |
Why?
|
| Thoracic Surgery | 1 | 2015 | 280 | 0.090 |
Why?
|
| Algorithms | 2 | 2020 | 3909 | 0.090 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2012 | 205 | 0.090 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2024 | 1331 | 0.090 |
Why?
|
| DNA Mutational Analysis | 3 | 2021 | 2351 | 0.090 |
Why?
|
| Comorbidity | 2 | 2016 | 2429 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2018 | 802 | 0.090 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2011 | 255 | 0.090 |
Why?
|
| Radiography, Thoracic | 1 | 2013 | 473 | 0.090 |
Why?
|
| Dyspnea | 1 | 2013 | 419 | 0.090 |
Why?
|
| Contrast Media | 2 | 2020 | 1510 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2011 | 9078 | 0.090 |
Why?
|
| Intestine, Small | 2 | 2020 | 526 | 0.090 |
Why?
|
| Receptor, ErbB-3 | 1 | 2010 | 126 | 0.090 |
Why?
|
| Brain Neoplasms | 2 | 2023 | 4982 | 0.090 |
Why?
|
| Organoplatinum Compounds | 1 | 2012 | 703 | 0.090 |
Why?
|
| Introns | 2 | 2010 | 460 | 0.090 |
Why?
|
| Acute Kidney Injury | 1 | 2017 | 789 | 0.090 |
Why?
|
| Purine-Nucleoside Phosphorylase | 1 | 2009 | 51 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 3398 | 0.080 |
Why?
|
| Duodenum | 2 | 2023 | 171 | 0.080 |
Why?
|
| Infant, Newborn | 1 | 2022 | 8597 | 0.080 |
Why?
|
| Wnt1 Protein | 1 | 2009 | 102 | 0.080 |
Why?
|
| Radiography | 2 | 2020 | 1989 | 0.080 |
Why?
|
| Hepatic Artery | 2 | 2022 | 256 | 0.080 |
Why?
|
| Cyclin A | 1 | 2008 | 50 | 0.080 |
Why?
|
| Giant Cell Tumors | 1 | 2008 | 33 | 0.080 |
Why?
|
| Registries | 1 | 2016 | 2231 | 0.080 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2024 | 1010 | 0.080 |
Why?
|
| Thyroid Neoplasms | 1 | 2019 | 1894 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2021 | 4511 | 0.080 |
Why?
|
| Sepsis | 1 | 2013 | 689 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2008 | 201 | 0.070 |
Why?
|
| Decision Support Techniques | 1 | 2013 | 605 | 0.070 |
Why?
|
| Ovarian Neoplasms | 1 | 2024 | 4774 | 0.070 |
Why?
|
| Neoplastic Stem Cells | 1 | 2016 | 1469 | 0.070 |
Why?
|
| Carcinoma, Papillary | 1 | 2011 | 581 | 0.070 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 806 | 0.070 |
Why?
|
| Brachytherapy | 1 | 2014 | 1005 | 0.070 |
Why?
|
| Gene Deletion | 2 | 2009 | 1482 | 0.070 |
Why?
|
| Hepatitis B | 1 | 2009 | 274 | 0.070 |
Why?
|
| Epidermal Growth Factor | 1 | 2007 | 445 | 0.070 |
Why?
|
| Cell Nucleus | 1 | 2011 | 1742 | 0.060 |
Why?
|
| Tumor Microenvironment | 3 | 2022 | 2984 | 0.060 |
Why?
|
| Motivation | 2 | 2019 | 509 | 0.060 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 474 | 0.060 |
Why?
|
| Polymorphism, Genetic | 2 | 2010 | 1522 | 0.060 |
Why?
|
| Skin Neoplasms | 1 | 2021 | 4840 | 0.060 |
Why?
|
| Liver Cirrhosis | 2 | 2023 | 1023 | 0.060 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2009 | 623 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 2282 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2010 | 2093 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2011 | 3654 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 3 | 2011 | 1215 | 0.060 |
Why?
|
| Hepatitis C | 1 | 2009 | 549 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2010 | 4956 | 0.060 |
Why?
|
| Abdominal Muscles | 1 | 2023 | 71 | 0.060 |
Why?
|
| Learning Curve | 1 | 2024 | 78 | 0.060 |
Why?
|
| Pancreaticojejunostomy | 1 | 2022 | 14 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2024 | 7950 | 0.050 |
Why?
|
| Radiation Tolerance | 1 | 2006 | 635 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2024 | 324 | 0.050 |
Why?
|
| Angiography | 1 | 2024 | 344 | 0.050 |
Why?
|
| Frozen Sections | 1 | 2022 | 118 | 0.050 |
Why?
|
| Observer Variation | 1 | 2024 | 723 | 0.050 |
Why?
|
| Social Class | 1 | 2023 | 320 | 0.050 |
Why?
|
| Aspartate Aminotransferases | 1 | 2022 | 148 | 0.050 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2023 | 212 | 0.050 |
Why?
|
| Cholangiography | 1 | 2021 | 35 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 5568 | 0.050 |
Why?
|
| Capecitabine | 1 | 2022 | 390 | 0.050 |
Why?
|
| Alanine Transaminase | 1 | 2022 | 240 | 0.050 |
Why?
|
| Genes, APC | 1 | 2021 | 72 | 0.050 |
Why?
|
| Benchmarking | 1 | 2023 | 284 | 0.050 |
Why?
|
| Epidemiologic Methods | 1 | 2021 | 252 | 0.050 |
Why?
|
| Patients | 1 | 2023 | 247 | 0.050 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2020 | 81 | 0.050 |
Why?
|
| Rectum | 1 | 2023 | 479 | 0.050 |
Why?
|
| Muscle, Skeletal | 2 | 2018 | 1312 | 0.050 |
Why?
|
| Fluorescence | 1 | 2021 | 201 | 0.050 |
Why?
|
| Canada | 1 | 2021 | 432 | 0.050 |
Why?
|
| Coloring Agents | 1 | 2021 | 237 | 0.040 |
Why?
|
| Perioperative Period | 1 | 2021 | 150 | 0.040 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 4394 | 0.040 |
Why?
|
| Interleukin-2 | 1 | 2024 | 891 | 0.040 |
Why?
|
| Operating Rooms | 1 | 2021 | 128 | 0.040 |
Why?
|
| Radiology, Interventional | 1 | 2021 | 142 | 0.040 |
Why?
|
| Blotting, Western | 3 | 2011 | 3649 | 0.040 |
Why?
|
| Indocyanine Green | 1 | 2021 | 127 | 0.040 |
Why?
|
| Organoids | 1 | 2022 | 316 | 0.040 |
Why?
|
| Surgical Wound Infection | 1 | 2023 | 470 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2008 | 2471 | 0.040 |
Why?
|
| Safety | 1 | 2021 | 466 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2023 | 1257 | 0.040 |
Why?
|
| Japan | 1 | 2019 | 233 | 0.040 |
Why?
|
| Physical Fitness | 1 | 2019 | 125 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2021 | 486 | 0.040 |
Why?
|
| Induction Chemotherapy | 1 | 2022 | 671 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2023 | 1036 | 0.040 |
Why?
|
| Retreatment | 1 | 2020 | 451 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2010 | 7295 | 0.040 |
Why?
|
| Anatomic Landmarks | 1 | 2018 | 51 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2022 | 671 | 0.040 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2019 | 161 | 0.040 |
Why?
|
| Medicaid | 1 | 2021 | 307 | 0.040 |
Why?
|
| Relative Value Scales | 1 | 2018 | 14 | 0.040 |
Why?
|
| Nucleic Acid Hybridization | 2 | 2009 | 633 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2021 | 1439 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2007 | 2198 | 0.040 |
Why?
|
| Streptozocin | 1 | 2018 | 72 | 0.040 |
Why?
|
| Drug Therapy | 1 | 2019 | 207 | 0.040 |
Why?
|
| Preliminary Data | 1 | 2017 | 14 | 0.040 |
Why?
|
| Vascular System Injuries | 1 | 2018 | 54 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2023 | 2621 | 0.040 |
Why?
|
| Hospitals, Low-Volume | 1 | 2018 | 53 | 0.040 |
Why?
|
| Subcutaneous Fat | 1 | 2017 | 67 | 0.040 |
Why?
|
| Ligaments | 1 | 2017 | 42 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2018 | 121 | 0.040 |
Why?
|
| Drug Substitution | 1 | 2017 | 86 | 0.040 |
Why?
|
| Pancreatic Diseases | 1 | 2018 | 112 | 0.040 |
Why?
|
| Water-Electrolyte Balance | 1 | 2017 | 118 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2017 | 165 | 0.040 |
Why?
|
| Radiographic Image Enhancement | 1 | 2020 | 410 | 0.040 |
Why?
|
| Intra-Abdominal Fat | 1 | 2017 | 94 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 7816 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2019 | 508 | 0.040 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 530 | 0.040 |
Why?
|
| Anastomosis, Surgical | 1 | 2018 | 372 | 0.040 |
Why?
|
| Schools, Medical | 1 | 2018 | 132 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2019 | 360 | 0.040 |
Why?
|
| In Situ Hybridization | 2 | 2011 | 1062 | 0.040 |
Why?
|
| Anthropometry | 1 | 2017 | 264 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2017 | 16981 | 0.030 |
Why?
|
| Reference Values | 1 | 2019 | 1156 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2019 | 991 | 0.030 |
Why?
|
| Biopsy | 2 | 2018 | 3555 | 0.030 |
Why?
|
| Genes, p53 | 1 | 2021 | 1135 | 0.030 |
Why?
|
| Models, Economic | 1 | 2016 | 102 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 1135 | 0.030 |
Why?
|
| Health Care Rationing | 1 | 2016 | 79 | 0.030 |
Why?
|
| AC133 Antigen | 1 | 2016 | 109 | 0.030 |
Why?
|
| Publishing | 1 | 2018 | 196 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2017 | 485 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 675 | 0.030 |
Why?
|
| Feces | 1 | 2019 | 863 | 0.030 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2017 | 366 | 0.030 |
Why?
|
| Glucose | 1 | 2021 | 1255 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 691 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2021 | 2151 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2016 | 239 | 0.030 |
Why?
|
| Exercise | 1 | 2023 | 1211 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2019 | 686 | 0.030 |
Why?
|
| Health Behavior | 1 | 2019 | 597 | 0.030 |
Why?
|
| Hyaluronan Receptors | 1 | 2016 | 250 | 0.030 |
Why?
|
| Glioma | 1 | 2006 | 1969 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2022 | 1201 | 0.030 |
Why?
|
| alpha-Fetoproteins | 1 | 2016 | 252 | 0.030 |
Why?
|
| Bacteria | 1 | 2019 | 654 | 0.030 |
Why?
|
| Health Services Needs and Demand | 1 | 2016 | 251 | 0.030 |
Why?
|
| Alkaline Phosphatase | 1 | 2014 | 220 | 0.030 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2016 | 260 | 0.030 |
Why?
|
| Up-Regulation | 2 | 2011 | 2465 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2020 | 1645 | 0.030 |
Why?
|
| Abdomen, Acute | 1 | 2014 | 38 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2024 | 2452 | 0.030 |
Why?
|
| Bile | 1 | 2013 | 85 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2024 | 6165 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 2013 | 259 | 0.030 |
Why?
|
| Aorta | 1 | 2017 | 682 | 0.030 |
Why?
|
| Quality Indicators, Health Care | 1 | 2016 | 364 | 0.030 |
Why?
|
| Pneumonectomy | 1 | 2018 | 863 | 0.030 |
Why?
|
| Tissue and Organ Procurement | 1 | 2016 | 235 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 2670 | 0.030 |
Why?
|
| Neutrophils | 1 | 2017 | 870 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 2048 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2020 | 2264 | 0.030 |
Why?
|
| Graft Survival | 1 | 2016 | 1098 | 0.030 |
Why?
|
| Infant | 1 | 2007 | 13920 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2013 | 234 | 0.020 |
Why?
|
| Suture Techniques | 1 | 2013 | 293 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 2335 | 0.020 |
Why?
|
| Child | 3 | 2018 | 30421 | 0.020 |
Why?
|
| Disease Management | 1 | 2017 | 1111 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2017 | 1589 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2018 | 3138 | 0.020 |
Why?
|
| Chromones | 1 | 2010 | 121 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2011 | 320 | 0.020 |
Why?
|
| Esophageal Neoplasms | 1 | 2024 | 3236 | 0.020 |
Why?
|
| Luciferases | 1 | 2011 | 462 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2011 | 512 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2017 | 2238 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 2020 | 2648 | 0.020 |
Why?
|
| Flavonoids | 1 | 2010 | 201 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2011 | 718 | 0.020 |
Why?
|
| Cancer Care Facilities | 1 | 2014 | 908 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2011 | 1158 | 0.020 |
Why?
|
| Morpholines | 1 | 2010 | 297 | 0.020 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2008 | 72 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2010 | 917 | 0.020 |
Why?
|
| Contraindications | 1 | 2008 | 156 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 7218 | 0.020 |
Why?
|
| Sex Factors | 1 | 2013 | 2192 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 1212 | 0.020 |
Why?
|
| Homozygote | 1 | 2009 | 759 | 0.020 |
Why?
|
| Phenotype | 1 | 2018 | 6465 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2010 | 698 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2010 | 1856 | 0.020 |
Why?
|
| RNA Interference | 1 | 2010 | 1398 | 0.020 |
Why?
|
| Chromosome Banding | 1 | 2006 | 280 | 0.020 |
Why?
|
| Cadherins | 1 | 2009 | 677 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2009 | 1119 | 0.020 |
Why?
|
| beta Catenin | 1 | 2009 | 690 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2010 | 1961 | 0.010 |
Why?
|
| Mice | 2 | 2019 | 35996 | 0.010 |
Why?
|
| Karyotyping | 1 | 2006 | 1065 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2011 | 3245 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2010 | 1725 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2011 | 5835 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 2490 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2011 | 4986 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2006 | 1586 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 5112 | 0.010 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2010 | 3919 | 0.010 |
Why?
|
| Genotype | 1 | 2009 | 4109 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2011 | 6492 | 0.010 |
Why?
|
| Animals | 2 | 2019 | 62871 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 4902 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2009 | 2736 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2006 | 5411 | 0.010 |
Why?
|